Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin
Status:
Completed
Trial end date:
2020-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of pembrolizumab in patient
with locally advanced or metastatic squamous cell carcinoma of the skin